Tempus AI CEO Lefkofsky Sold $6.6M in Shares Day Before 24% Rally

The Quick Take

• Tempus AI CEO Lefkofsky sold $6.6M (133,000 shares at $49.61) one day before a major stock rally
• A Director (West) also sold 3,000 shares at $53.90 four days before a separate 24% single-day rally
• Multiple executives' sales executed under pre-established Rule 10b5-1 plans; no insider knowledge implied legally

The proximity of Tempus AI CEO Eric Lefkofsky's $6.6 million sale — disposing of 133,000 shares at a weighted average price of $49.61, one day before a significant stock rally — has drawn widespread attention across five reporting outlets, though the legal structure is unambiguous: the transaction was executed under a pre-established Rule 10b5-1 trading plan that requires sales to be predetermined without knowledge of subsequent market events. The same legal framework applies to Director West's 3,000-share, $161,700 sale four days before a 24% single-day rally. Both transactions were filed as non-discretionary, with proceeds pre-committed to tax withholding or plan schedules.

Despite the legal clarity, the optics are damaging in the context of a stock that has surged 75% in recent months — leaving retail investors who bought after the insider sales at prices significantly above the executives' disposal prices. The pattern of multiple Tempus AI insiders selling near peaks — while legal under Rule 10b5-1 — fuels legitimate debate about whether 10b5-1 plans should require longer cooling-off periods between plan adoption and first execution, a reform the SEC has been exploring. At the company level, the retained holdings of executives post-sale remain significant, maintaining some alignment.

For investors assessing Tempus AI's fundamental case, the insider sale pattern is analytically less relevant than the business trajectory: whether Tempus AI's clinical AI licensing model can convert its growing hospital system partnerships into durable recurring revenue at margins that justify the current multiple. Watch for any SEC rulemaking on 10b5-1 plan reforms that would constrain executive flexibility in timing sales, as well as Tempus AI's next earnings call where management will need to address both the operational roadmap and restore investor confidence after the insider-sale optics.

Synthesized from 5 sources.